News
Why weight loss giant Novo Nordisk dumped its CEO
The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO the door. Novo Nordisk announced Friday that Lars Fruergaard Jorgensen is stepping down by “mutual agreement” with the board—corporate speak for “things aren’t going well and someone has to take the fall.”
1don MSN
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Newer medications, such as Mounjaro and Wegovy, exhibit both more total weight lost and faster weight regain than older ...
Everyday Health on MSN2d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback